Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that the first patients with diabetic retinopathy have been treated in the Phase 3 GLOW2 study of tarcocimab tedromer. This milestone marks a significant advancement in the ongoing research and development efforts aimed at combating retinal diseases. Key […]
Kodiak Sciences said that its antibody biopolymer conjugate KSI-301 failed to meet the primary endpoint in a phase 2b/3 clinical trial in neovascular (wet) age-related macular degeneration (wet AMD). The primary endpoint of the trial was achieving non-inferior visual acuity gains with the treatment of KSI-301, which is an anti–vascular endothelial growth factor therapy (anti-VEGF […]
KSI-301 phase 1b trial : Kodiak Sciences said that its ongoing phase 1b clinical trial of its intravitreal anti-VEGF antibody biopolymer conjugate KSI-301 for the treatment of patients with treatment-naïve wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), has yielded promising additional safety, efficacy and durability data. According […]
Kodiak Sciences said that it has treated the first patients in the phase 2 DAZZLE clinical trial of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate, in wet age-related macular degeneration (wet AMD). The DAZZLE trial (also called KSI-CL-102) is designed to assess the safety and efficacy of KSI-301 in AMD patients who are treatment-naïve. […]
Kodiak Sciences, a California-based biotechnology company, has recently completed patient enrollment for a phase 1 safety and tolerability study of its innovative retinal disease drug, KSI-301. This study marks a significant step in the clinical development of KSI-301, which is being tested primarily on patients with diabetic macular edema in the United States. The phase […]